![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENDOD1 |
Gene summary for ENDOD1 |
![]() |
Gene information | Species | Human | Gene symbol | ENDOD1 | Gene ID | 23052 |
Gene name | endonuclease domain containing 1 | |
Gene Alias | ENDOD1 | |
Cytomap | 11q21 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O94919 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23052 | ENDOD1 | SYSMH3 | Human | Oral cavity | OSCC | 9.26e-19 | 3.87e-01 | 0.2442 |
23052 | ENDOD1 | SYSMH5 | Human | Oral cavity | OSCC | 1.04e-08 | 3.45e-01 | 0.0647 |
23052 | ENDOD1 | SYSMH6 | Human | Oral cavity | OSCC | 7.71e-03 | 1.78e-01 | 0.1275 |
23052 | ENDOD1 | Dong_P3 | Human | Prostate | Tumor | 4.14e-05 | 6.62e-02 | 0.0278 |
23052 | ENDOD1 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 2.52e-02 | 6.71e-01 | 0.159 |
23052 | ENDOD1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 6.62e-07 | 5.44e-01 | 0.1633 |
23052 | ENDOD1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.24e-07 | 5.19e-01 | 0.1608 |
23052 | ENDOD1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 4.28e-07 | 5.75e-01 | 0.1604 |
23052 | ENDOD1 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 1.36e-02 | 5.37e-01 | 0.1608 |
23052 | ENDOD1 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 4.32e-03 | 6.64e-01 | 0.1622 |
23052 | ENDOD1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 6.18e-03 | 3.30e-01 | 0.1545 |
23052 | ENDOD1 | P1_cSCC | Human | Skin | cSCC | 4.27e-19 | 5.99e-01 | 0.0292 |
23052 | ENDOD1 | P2_cSCC | Human | Skin | cSCC | 8.01e-09 | 3.26e-01 | -0.024 |
23052 | ENDOD1 | P4_cSCC | Human | Skin | cSCC | 2.15e-11 | 3.27e-01 | -0.00290000000000005 |
23052 | ENDOD1 | P10_cSCC | Human | Skin | cSCC | 1.56e-15 | 4.40e-01 | 0.1017 |
23052 | ENDOD1 | cSCC_p10 | Human | Skin | cSCC | 3.63e-02 | 1.10e-01 | -0.2095 |
23052 | ENDOD1 | cSCC_p8 | Human | Skin | cSCC | 7.97e-03 | 6.95e-02 | -0.1971 |
23052 | ENDOD1 | male-WTA | Human | Thyroid | PTC | 4.42e-29 | 3.67e-01 | 0.1037 |
23052 | ENDOD1 | female-WTA | Human | Thyroid | PTC | 2.72e-04 | 2.56e-01 | 0.0726 |
23052 | ENDOD1 | PTC01 | Human | Thyroid | PTC | 3.36e-18 | 4.55e-01 | 0.1899 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:00903052 | Oral cavity | OSCC | nucleic acid phosphodiester bond hydrolysis | 142/7305 | 261/18723 | 2.90e-07 | 4.43e-06 | 142 |
GO:00903051 | Oral cavity | LP | nucleic acid phosphodiester bond hydrolysis | 92/4623 | 261/18723 | 8.07e-05 | 1.04e-03 | 92 |
GO:00903054 | Skin | cSCC | nucleic acid phosphodiester bond hydrolysis | 97/4864 | 261/18723 | 4.08e-05 | 4.34e-04 | 97 |
GO:00903055 | Thyroid | PTC | nucleic acid phosphodiester bond hydrolysis | 105/5968 | 261/18723 | 2.53e-03 | 1.31e-02 | 105 |
GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENDOD1 | SNV | Missense_Mutation | novel | c.1188N>A | p.Ser396Arg | p.S396R | O94919 | protein_coding | deleterious(0) | possibly_damaging(0.795) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ENDOD1 | SNV | Missense_Mutation | novel | c.184N>A | p.Ala62Thr | p.A62T | O94919 | protein_coding | tolerated(0.5) | benign(0.138) | TCGA-LD-A9QF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
ENDOD1 | insertion | In_Frame_Ins | novel | c.914_915insGGGGACTTCTCCAGAGTCTGGGCAGGATGA | p.Leu305_Ser306insGlyThrSerProGluSerGlyGlnAspAsp | p.L305_S306insGTSPESGQDD | O94919 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
ENDOD1 | insertion | Frame_Shift_Ins | novel | c.1223_1224insGG | p.Ile409AlafsTer13 | p.I409Afs*13 | O94919 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ENDOD1 | insertion | Nonsense_Mutation | novel | c.1225_1226insGTCCCTGAGTTTGTTTGGCTGGCAGCC | p.Ile409delinsSerProTerValCysLeuAlaGlySerLeu | p.I409delinsSP*VCLAGSL | O94919 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ENDOD1 | SNV | Missense_Mutation | novel | c.478N>G | p.Leu160Val | p.L160V | O94919 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ENDOD1 | SNV | Missense_Mutation | c.1152N>G | p.Ile384Met | p.I384M | O94919 | protein_coding | tolerated(0.18) | benign(0.1) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ENDOD1 | SNV | Missense_Mutation | novel | c.1055C>T | p.Ala352Val | p.A352V | O94919 | protein_coding | tolerated(0.24) | benign(0.107) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ENDOD1 | SNV | Missense_Mutation | novel | c.1385N>T | p.Thr462Ile | p.T462I | O94919 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ENDOD1 | SNV | Missense_Mutation | novel | c.841N>C | p.Lys281Gln | p.K281Q | O94919 | protein_coding | tolerated(0.15) | probably_damaging(0.939) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |